Neo Ivy Capital Management Acquires New Position in Agilent Technologies, Inc. $A

Neo Ivy Capital Management purchased a new stake in shares of Agilent Technologies, Inc. (NYSE:A) during the third quarter, Holdings Channel reports. The institutional investor purchased 9,376 shares of the medical research company’s stock, valued at approximately $1,203,000.

Several other institutional investors and hedge funds also recently bought and sold shares of A. Resona Asset Management Co. Ltd. boosted its holdings in shares of Agilent Technologies by 6.2% in the second quarter. Resona Asset Management Co. Ltd. now owns 98,400 shares of the medical research company’s stock worth $11,631,000 after acquiring an additional 5,767 shares during the period. Envestnet Asset Management Inc. raised its stake in shares of Agilent Technologies by 3.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 607,914 shares of the medical research company’s stock valued at $78,026,000 after purchasing an additional 22,498 shares during the period. CCLA Investment Management raised its stake in shares of Agilent Technologies by 10.5% during the 3rd quarter. CCLA Investment Management now owns 1,027,970 shares of the medical research company’s stock valued at $131,909,000 after purchasing an additional 97,312 shares during the period. Nuance Investments LLC lifted its holdings in Agilent Technologies by 13.5% during the 2nd quarter. Nuance Investments LLC now owns 80,698 shares of the medical research company’s stock worth $9,523,000 after purchasing an additional 9,628 shares in the last quarter. Finally, Osaic Holdings Inc. lifted its holdings in Agilent Technologies by 35.5% during the 2nd quarter. Osaic Holdings Inc. now owns 68,053 shares of the medical research company’s stock worth $8,017,000 after purchasing an additional 17,817 shares in the last quarter.

Agilent Technologies Stock Performance

NYSE:A opened at $115.11 on Friday. The company has a market capitalization of $32.53 billion, a price-to-earnings ratio of 25.41, a PEG ratio of 2.42 and a beta of 1.31. The business has a 50 day moving average of $132.65 and a 200 day moving average of $136.00. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.07 and a quick ratio of 1.59. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $160.27.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, February 25th. The medical research company reported $1.36 EPS for the quarter, missing the consensus estimate of $1.37 by ($0.01). The firm had revenue of $1.80 billion during the quarter, compared to analysts’ expectations of $1.81 billion. Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%.The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. On average, sell-side analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 22nd. Stockholders of record on Tuesday, March 31st will be paid a $0.255 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.9%. Agilent Technologies’s payout ratio is currently 22.52%.

Analyst Upgrades and Downgrades

A has been the subject of a number of analyst reports. HSBC initiated coverage on shares of Agilent Technologies in a research report on Tuesday, January 20th. They issued a “buy” rating and a $180.00 price objective for the company. Citigroup increased their target price on shares of Agilent Technologies from $165.00 to $185.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. UBS Group cut their price target on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a report on Thursday, February 26th. The Goldman Sachs Group assumed coverage on shares of Agilent Technologies in a research report on Tuesday, December 9th. They set a “buy” rating and a $170.00 price target for the company. Finally, TD Cowen decreased their price target on shares of Agilent Technologies from $170.00 to $157.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $161.20.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.